SEP-479 (PTH1R)
Hypoparathyroidism
Phase 2Active
Key Facts
About Septerna
Septerna's mission is to unlock the vast therapeutic potential of G protein-coupled receptors (GPCRs), a historically productive but still largely underexploited target class. The company has achieved rapid progress, advancing its wholly-owned lead programs into Phase 2 and Phase 1 clinical trials, powered by its industrial-scale Native Complex Platform®. Its strategy combines internal development of high-value, biomarker-driven programs with selective partnerships for complex indications, aiming to deliver a portfolio of novel, oral, disease-modifying medicines.
View full company profileTherapeutic Areas
Other Hypoparathyroidism Drugs
| Drug | Company | Phase |
|---|---|---|
| Oral Long-Acting PTH Tablet | Opko Health | Preclinical |
| EB-612 | Extend Biosciences | Phase 2 |
| Hypoparathyroidism Program | Confo Therapeutics | Discovery |
| Canvuparatide (MBX 2109) | MBX Biosciences | Phase 2 |
| EB612 (oral PTH(1-34)) | Entera Bio | Phase 2 |
| Oral Long-Acting PTH | Entera Bio | Discovery/Preclinical |